S&P 500   3,088.90 (-0.10%)
DOW   27,674.87 (-0.06%)
QQQ   201.35 (-0.09%)
BABA   184.25 (-1.45%)
GE   11.28 (-1.23%)
T   39.21 (+0.08%)
F   8.95 (-1.00%)
ACB   3.52 (-1.40%)
PRI   128.33 (-1.25%)
DIS   137.76 (-0.60%)
S&P 500   3,088.90 (-0.10%)
DOW   27,674.87 (-0.06%)
QQQ   201.35 (-0.09%)
BABA   184.25 (-1.45%)
GE   11.28 (-1.23%)
T   39.21 (+0.08%)
F   8.95 (-1.00%)
ACB   3.52 (-1.40%)
PRI   128.33 (-1.25%)
DIS   137.76 (-0.60%)
Log in

Evogene Stock Price, Forecast & Analysis (NASDAQ:EVGN)

$1.50
-0.08 (-5.06 %)
(As of 11/13/2019 10:00 AM ET)
Today's Range
$1.50
Now: $1.50
$1.50
50-Day Range
$1.52
MA: $1.61
$1.73
52-Week Range
$1.34
Now: $1.50
$2.71
Volume300 shs
Average Volume19,181 shs
Market Capitalization$38.63 million
P/E RatioN/A
Dividend YieldN/A
Beta1.21
Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics. Read More…

Industry, Sector and Symbol

Industry Agricultural chemicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:EVGN
CUSIPN/A
Phone972-8931-1900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.75 million
Book Value$1.95 per share

Profitability

Net Income$-20,760,000.00
Net Margins-1,193.65%

Miscellaneous

EmployeesN/A
Market Cap$38.63 million
Next Earnings Date11/13/2019 (Confirmed)
OptionableNot Optionable

Receive EVGN News and Ratings via Email

Sign-up to receive the latest news and ratings for EVGN and its competitors with MarketBeat's FREE daily newsletter.


Evogene (NASDAQ:EVGN) Frequently Asked Questions

What is Evogene's stock symbol?

Evogene trades on the NASDAQ under the ticker symbol "EVGN."

How were Evogene's earnings last quarter?

Evogene Ltd (NASDAQ:EVGN) released its earnings results on Tuesday, May, 29th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.02. The biotechnology company had revenue of $0.37 million for the quarter. Evogene had a negative return on equity of 37.62% and a negative net margin of 1,193.65%. View Evogene's Earnings History.

When is Evogene's next earnings date?

Evogene is scheduled to release their next quarterly earnings announcement on Wednesday, November 13th 2019. View Earnings Estimates for Evogene.

Has Evogene been receiving favorable news coverage?

News headlines about EVGN stock have trended very negative on Wednesday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evogene earned a daily sentiment score of -3.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for Evogene.

Are investors shorting Evogene?

Evogene saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 8,800 shares, a drop of 17.0% from the September 30th total of 10,600 shares. Based on an average daily trading volume, of 7,100 shares, the days-to-cover ratio is presently 1.2 days. Approximately 0.0% of the shares of the stock are sold short. View Evogene's Current Options Chain.

Who are some of Evogene's key competitors?

What other stocks do shareholders of Evogene own?

Who are Evogene's key executives?

Evogene's management team includes the folowing people:
  • Mr. Ofer Haviv, CEO & Pres (Age 53)
  • Ms. Dorit Kreiner, Interim Chief Financial Officer
  • Mr. Mark Kapel, Exec. VP of Technology (Age 42)
  • Dr. Eyal Emmanuel, Chief Scientific Officer (Age 46)
  • Ms. Sigal Fattal, Exec. Officer (Age 48)

How do I buy shares of Evogene?

Shares of EVGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Evogene's stock price today?

One share of EVGN stock can currently be purchased for approximately $1.50.

How big of a company is Evogene?

Evogene has a market capitalization of $38.63 million and generates $1.75 million in revenue each year. View Additional Information About Evogene.

What is Evogene's official website?

The official website for Evogene is http://www.evogene.com/.

How can I contact Evogene?

Evogene's mailing address is 13 GAD FEINSTEIN STREET PARK REHOVOT P.O.B 2100, REHOVOT L3, 76121. The biotechnology company can be reached via phone at 972-8931-1900 or via email at [email protected]


MarketBeat Community Rating for Evogene (NASDAQ EVGN)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  192 (Thanks for Voting!)
Underperform Votes:  235 (Thanks for Voting!)
Total Votes:  427
MarketBeat's community ratings are surveys of what our community members think about Evogene and other stocks. Vote "Outperform" if you believe EVGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EVGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2019 by MarketBeat.com Staff

Featured Article: Cost of Capital Explained

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel